Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Victory Capital Management Inc.

Victory Capital Management Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 51.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 82,386 shares of the biopharmaceutical company’s stock after selling 87,892 shares during the quarter. Victory Capital Management Inc. owned approximately 0.08% of Regeneron Pharmaceuticals worth $46,323,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at approximately $27,000. Migdal Insurance & Financial Holdings Ltd. purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $31,000. Caitlin John LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $34,000. Traub Capital Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the second quarter worth $38,000. Finally, E Fund Management Hong Kong Co. Ltd. grew its stake in shares of Regeneron Pharmaceuticals by 87.5% during the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 35 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of analysts have weighed in on the company. Guggenheim raised their price target on Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the company a “buy” rating in a research note on Monday, February 9th. HSBC initiated coverage on Regeneron Pharmaceuticals in a research report on Monday, November 24th. They set a “buy” rating and a $255.00 price objective for the company. Royal Bank Of Canada increased their price objective on Regeneron Pharmaceuticals from $745.00 to $765.00 and gave the company a “sector perform” rating in a report on Monday, March 2nd. JPMorgan Chase & Co. raised their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the stock an “overweight” rating in a research report on Monday, February 2nd. Finally, Barclays began coverage on Regeneron Pharmaceuticals in a research note on Friday. They set an “overweight” rating and a $923.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $802.27.

Regeneron Pharmaceuticals Trading Down 0.7%

NASDAQ:REGN opened at $759.82 on Friday. The company has a market capitalization of $80.33 billion, a PE ratio of 18.28, a P/E/G ratio of 2.04 and a beta of 0.41. Regeneron Pharmaceuticals, Inc. has a 52-week low of $476.49 and a 52-week high of $821.11. The stock’s 50 day moving average price is $770.81 and its 200 day moving average price is $688.75. The company has a quick ratio of 3.39, a current ratio of 4.13 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The company had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The firm’s revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $12.07 earnings per share. On average, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were issued a $0.94 dividend. The ex-dividend date of this dividend was Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.05%.

Insider Buying and Selling

In other news, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.52, for a total value of $1,585,066.72. Following the sale, the senior vice president owned 4,272 shares of the company’s stock, valued at $3,325,837.44. The trade was a 32.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director directly owned 17,803 shares of the company’s stock, valued at approximately $13,860,169.59. This trade represents a 0.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 5,274 shares of company stock valued at $4,142,738 in the last ninety days. Company insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.